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Abstract
Background: Hyperbaric oxygen therapy (HBOT) is a known adjuvant for treating ischemia-related inner ear
diseases. Controversies still exist in the role of HBOT in cochlear diseases. Few studies to date have investigated the
cellular changes that occur in inner ears after HBOT. Nitric oxide, which is synthesized by nitric oxide synthase
(NOS), is an important signaling molecule in cochlear physiology and pathology. Here we investigated the effects
of hyperbaric oxygen on eardrum morphology, cochlear function and expression of NOS isoforms in cochlear
substructures after repetitive HBOT in guinea pigs.
Results: Minor changes in the eardrum were observed after repetitive HBOT, which did not result in a significant
hearing threshold shift by tone burst auditory brainstem responses. A differential effect of HBOT on the expression
of NOS isoforms was identified. Upregulation of constitutive NOS (nNOS and eNOS) was found in the substructures
of the cochlea after HBOT, but inducible NOS was not found in normal or HBOT animals, as shown by
immunohistochemistry. There was no obvious DNA fragmentation present in this HBOT animal model.
Conclusions: The present evidence indicates that the customary HBOT protocol may increase constitutive NOS
expression but such upregulation did not cause cell death in the treated cochlea. The cochlear morphology and
auditory function are consequently not changed through the protocol.
Background
Hyperbaric oxygen therapy (HBOT) is an effective treat-
ment for decompression Sickness (DCS) and arterial gas
embolism (AGE) [1], and is proposed as an adjunct in
treating ischemia-related inner ear diseases [2-4], sudden
deafness [4,5], and acute noise trauma [6,7]. The efficacy
of HBOT in treating these inner ear diseases is variable,
and the mechanism of HBOT in inner ears is still not
fully understood. For example, HBOT has been pro-
posed to be an effective rescue strategy for noise trauma
[6,7]; however, one study found that HBOT had an
adverse effect on the inner ear after noise trauma [8].
Consequently, a high degree of medical skepticism still
exists regarding the role of HBOT in treating inner ear
diseases. More studies on the functional and cellular
changes that occur after HBOT may help to elucidate
these conflicting results.
Nitric oxide (NO) has important roles in cochlear
physiology, including neurotransmission [9], regulation
of cochlear blood flow [10,11], homeostasis of cochlear
endolymph [11] and induction of cytotoxicity under
pathological conditions [12,13]. NO is synthesized by
nitric oxide synthase (NOS) with the conversion of
L-arginine to L-citrulline. Three isoforms of homologous
NOS have been identified, including two constitutive
isoforms (neuronal NOS [nNOS or NOS I] and
endothelial NOS [eNOS or NOS III]) and one inducible
isoform (iNOS or NOS II) [11,14,15]. Constitutive NOS
is calcium/calmodulin dependent and is continuously
expressed, whereas iNOS is calcium independent and is
expressed in response to specific stimulants such as
cytokines or endotoxins [12]. Constitutive isoforms of
NOS, both nNOS and eNOS, are expressed in the nor-
mal cochlea [16], but iNOS is expressed in the cochlea
only after exposure to some pathologic conditions such
as endotoxins [12], ischemia [13] or acoustic trauma
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chemical staining.
Results
No significant auditory changes after repetitive
customary HBOT
All the animals in the experimental group tolerated the
entire course of HBOT without signs of irritability or
discomfort. All eardrums were checked and were found
to be normal before the study. After 20 HBOT sessions,
one ear still remained clean and normal without evi-
dence of hemorrhage (Teed grade 0), one ear showed
slight vascular injection (Teed grade 1), seven ears
developed minor hemorrhage (Teed grade 2) and one
ear developed moderate hemorrhage in the eardrum
(Teed grade 3; Figure 1). No hemotympanum or ear-
drum perforation was observed in the experimental
group. The eardrum condition in the control group
remained normal throughout the duration of this study.
Tone burst auditory brainstem responses (ABRs) were
used to assess hearing before and after HBOT (Figure
2). In the control normobaric air (NBA) and experimen-
tal HBOT groups, the intragroup hearing level prior to
the study and four weeks after commencing the study
did not significantly differ. Although slight elevated
hearing level at 1 kHz was recorded in the NBA group,
the intergroup hearing level between the control NBA
and experimental HBOT groups did not significantly
differ (Figure 2).
Differential expression of NOS isoforms in different
cochlear regions after repetitive HBOT
The immunohistochemical results for NOS expression
in cochleae from the control group and the experimen-
tal group are illustrated in Figures 3, 4 and 5. In
the control NBA group, nNOS exhibited moderate
immunoreactivity in the spiral ganglion and stria vascu-
laris and faint immunoreactivity in the modiolar nerve
fibers, afferent nerve fibers, limbus and organ of Corti
(Figure 3A). In the experimental HBOT group,
enhanced immunoreactivity of nNOS was present in the
spiral ganglion, modiolar nerve fibers, afferent nerve
fibers and stria vascularis (Figure 3B). Using semi-quan-
titative morphometric analysis, significant enhanced
immunoreactivity of nNOS was noted in the nerve fiber
bundles in the HBOT group (Figure 4A).
Immunohistochemistry using the antibody against eNOS
in the control NBA group revealed moderate immunor-
eactivity in the stria vascularis, organ of Corti, limbus,
spiral ganglion and modiolar blood vessels (Figure 3C). In
the experimental HBOT group, enhanced immunoreactiv-
ity of eNOS was present in the spiral ganglion, modiolar
blood vessels, limbus and stria vascularis (Figure 3D).
Significantly enhanced eNOS immunoreactivity was noted
in the modiolar blood vessels, nerve fibers and the limbus
in the HBOT group (Figure 4B).
Immunohistochemistry using the antibody against
iNOS did not reveal immunoreactivity in the NBA and
HBOT groups, as compared with the iNOS expression in
the positive control spleen tissue (Figures 3E, 3F and 3G).
To assess the co-expression of nNOS and eNOS in
the cochlea after HBOT, we used confocal microscopy
(Figure 5). Co-expression of nNOS and eNOS was
noted in the spiral ganglion and stria vascularis. Single
expression of eNOS immunoreactivity was also present
in the capillaries within the spiral ganglion region 7
(Figure 5). In the cochlear modiolus, nNOS was
expressed in the modiolar nerve fibers, whereas eNOS
was expressed along the modiolar blood vessels.
Figure 1 Morphology of eardrum after HBOT. Otoscopic view of
the eardrums in guinea pigs. A. normal eardrum; B. Image of the
eardrum with moderate hemorrhage (arrow) after 20 sessions of
HBOT.
Figure 2 Auditory level. Box plots of the hearing level in the
control, normobaric air (NBA) group and the experimental,
hyperbaric oxygen (HBO) treatment group before (_pre) and
4 weeks after (_4w) the treatment sessions. There were no
significant intra-group changes or inter-group differences in the
hearing levels before and 4 weeks after the start of the treatment.
X-axis indicates the different frequencies for auditory measurement,
from 1 k to 8 k Hz. The dots represent the outliers.
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Page 2 of 10Figure 3 Immunohistochemistry of NOS subtypes in cochlea. Immunohistochemistry of cochlear nNOS (A,B), eNOS (C,D) and iNOS (E,F)
expression in the control NBA and HBOT groups. (G) Spleen tissue was used as a positive control for iNOS. (H) Schematic drawing depicting a
cross-section through cochlear canals and its related sub-structures. (A,B) nNOS immunoreactivity was present in the spiral ganglion, stria
vascularis, organ of Corti, limbus and modiolar nerve bundles in both groups but enhanced immunoreactivity was present in the HBOT group.
(C,D) eNOS immunoreactivity was found in the modiolar blood vessels, stria vascularis, organ of Corti, limbus and spiral ganglion in both groups
with more enhanced immunoreactivity in the HBOT group. iNOS did not exhibit immunoreactivity in the control NBA (E) and HBOT (F) groups,
as compared with the positive control of iNOS expression in the spleen tissue (G). Scale bar, 50 μm.
Lin et al. BMC Neuroscience 2011, 12:21
http://www.biomedcentral.com/1471-2202/12/21
Page 3 of 10No obvious DNA fragmentation after HBOT by
TUNEL assay
To determine if there was any DNA fragmentation or
apoptotic cell death after HBOT, we used the TUNEL
assay to evaluate the cellular changes after HBOT. DNA
fragmentation and possible apoptotic cell death were
observed in the positive control obtained from brain tis-
sue with penetrating damage (Figures 6A, 6B and 6C);
however, no DNA fragmentation was found in the
cochlear tissue after HBOT (Figures 6D, 6E and 6F).
Discussion
Our present study, which was designed according to the
HBOT protocol used in clinical practice for acute cere-
bral ischemia [18], provides a functional measurement
and immunohistochemical evidence of cochlear NOS
changes as well as morphological evaluation of the ear-
drum after HBOT. HBOT effects on hearing may be
caused by decompression illnesses or barotraumas to
the middle or inner ear [19]. A slight increase in hearing
sensitivity is evident in animals receiving extreme acute
hyperbaric conditions [20]. The increased hearing sensi-
tivity may be caused by changes in the tympanic mem-
brane and middle ear impedance, which may be altered
under hyperbaric conditions [20]. In this study, the tym-
panic membrane and mesotympanum were observed by
otoscopy after repetitive HBOT. No significant changes
in tympanic membrane or mesotympanic injury were
observed, with the exception of one ear with moderate
hemotympanum (Figure 1). Because of their widely
patent Eustachian tube, guinea pigs have been shown to
tolerate compression well, with minimal middle/inner
ear barotrauma even under rapid compression rates
such as 2 ATA in 2 seconds [21]. Any barotrauma due
to repetitive HBOT might gradually improve without
significant sequelae [22]. Therefore, the hearing thresh-
old was not significantly affected by the minor changes
in the eardrum and middle ear (Figure 2).
Transient deterioration of cochlear function during the
initial exposure to HBOT has been observed in guinea
pigs and rabbits, which has been attributed to the vaso-
constriction of cochlear blood vessels during the initial
exposure to hyperbaric oxygen [23]. Hyperbaric oxygen
causes a slight morphologic alteration in the outer hair
cells of newborn rats [24]. After repetitive HBOT, minor
changes in cochlear function were observed including
cochlear degeneration, inner hair cell damage and
hemorrhage in the perilymphatic space and scala media
[25]. The cochlear hemorrhage phenomenon after hyper-
baric treatment was also reported in rats [26]. The
cochlear changes observed in these studies [25,26] might
be caused by higher-pressure conditions and a more-
rapid compression-decompression process, since
cochlear degeneration and he m o r r h a g ew e r em o r ep r o -
nounced under higher-pressure conditions (up to 5
ATA) [25]. In that study, the rate of compression was
>0.3 ATA/min, and decompression was about 0.5 ATA/
min. These conditions exceed the standard HBOT proto-
cols used in clinical practice. With slower compression-
decompression procedures and more modest maximum
compression pressures, no significant changes in hearing
levels were observed after repetitive HBOT [22,27]. In
this study, a slower compression-decompression protocol
(≤0.2 ATA/min) and lower peak pressure (2.5 ATA)
more closely mimic the current HBOT protocol used in
clinical practice. It is of note that no significant shifts in
the hearing level or cell death by TUNEL assay were
observed before and after HBOT using this animal
model. We suggest the results of this study more accu-
rately reflect the clinical effects of HBOT on the cochlea.
The elevation of the hydrostatic pressure while breath-
ing oxygen during HBOT will increase the partial oxygen
Figure 4 Morphometric analysis of nNOS and eNOS. Box plots
of the optical densities from morphometric measurements of nNOS
(A) and eNOS (B) in the control NBA (in white box) and
experimental HBO treatment group (in dash box). The expression of
nNOS was significantly enhanced in nerve fiber bundles after HBOT.
The expression of eNOS was significantly enhanced in the limbus,
nerve fiber bundles and modiolar blood vessels after HBOT. The
dots represent the outliers. OD, optical densities; SL, spiral ligament;
SV, stria vascularis; OG, organ of Corti.
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Page 4 of 10in target tissues providing the animal has a functioning
cardiorespiratory system and the target tissue is perfused.
After hyperbaric treatment at 2.5 ATA with pure oxygen,
partial oxygen pressure in the cochlear perilymph may
increase by up to 5-fold [2]. By this mechanism, HBOT
may be effective for sudden sensorineural hearing loss
where ischemia may be the cause [4,5]. This may also
include noise-induced hearing loss [6,7]. In addition to ele-
vation of partial oxygen pressure, oxidative stress is
believed to be fundamental to the therapeutic mechanisms
for HBOT [28]. Reactive nitrogen species, including NO,
contribute to this stress [28]. NO is synthesized by differ-
ent NOS isoforms and the expression of these isoforms
varies both from tissue to tissue and with the application
of HBOT. We might therefore expect a range of effects
from HBOT in different target tissues. The cerebrovascu-
lar responses to hyperoxia may be modulated by eNOS
and nNOS-derived NO [29]. Hyperbaric oxygen exposure
may enhance sensitivity to seizure because of the early cer-
ebral vasoconstriction by eNOS-derived NO [30].
Figure 5 Confocal microscopic view of eNOS and nNOS after HBOT. Immunofluorescence labeling of eNOS (red) and nNOS (green) in the
spiral ganglion (A-C), cochlear modiolus (D-F) and stria vascularis (G-I) of the cochlea after repetitive HBOT. Co-expression of eNOS and nNOS
occurred in the spiral ganglion (C) and stria vascularis (I). In the cochlear modiolus, nNOS was expressed in the modiolar nerve fibers, and eNOS
was expressed along the modiolar blood vessel. Scale bar, 20 μm.
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in the brain, which may promote an imbalance between
glutamatergic and GABAergic synaptic function and the
genesis of oxygen-induced seizures [31]. In contrast,
HBOT preconditioning may protect myocardium from
subsequent ischemia/hypoxia by way of upregulating
eNOS [32]. Therefore, HBO may be beneficial or harmful
depending on the type of tissue.
Different NOS isoforms are expressed in discrete
regions of the cochlea. The constitutive NOS, nNOS
and eNOS, are distributed in the substructures of the
cochlea under normal physiologic conditions [16].
nNOS immunoreactivity is found in the hair cells, spiral
ganglion, stria vascularis, spiral ligaments, limbus and
nerve fibers and spiral ganglion, whereas eNOS immu-
noreactivity is present in the endothelium of the
cochlear microvascular trees, stria vascularis, limbus and
the spiral ganglion [14,16]. iNOS was not found in the
structures of the normal cochlea [15]. iNOS is expressed
in the cochlea only after exposure to some pathologic
condition such as endotoxin [12], ischemia [13] or
acoustic trauma [16,17]. In this study, the distribution of
nNOS and eNOS was similar to that of previous studies
[14,16]. nNOS was distributed in the spiral ganglion,
nerve fiber bundles, stria vascularis, limbus and hair
cells. eNOS was distributed along the microvascular
structures in the cochlea such as the endothelium of
blood vessels in the modiolus, stria vascularis, spiral
ganglion and limbus. After repetitive HBOT, constitutive
NOS immunoreactivity was enhanced in these regions
(Figure 3). Morphometric analysis depicted the signifi-
cantly enhanced immunoreactivity of nNOS in nerve
fiber bundles and that of eNOS in nerve fiber bundles,
limbus and modiolar blood vessels (Figure 4). Marginally
significant enhanced immunoreactivity was demon-
strated in stria vascularis and spiral ganglion. Co-expres-
sion of eNOS and nNOS was also shown in stria
vascularis and spiral ganglion after HBOT (Figure 5).
These indicate that the possible therapeutic role of
H B O Tm a yb et h r o u g ht h eu p r e g u l a t i o no fc o n s t i t u t i v e
NOS in the cochlear neurovascular substructures since
mild elevation of NO may provide a neuroprotective
effect on auditory hair cells under ischemic condition
[15]. We have 10 cochleae for each group in this study.
Regarding the marginal significance in some effects such
as spiral ganglion and stria vascularis, our study was
underpowered to determine the statistical significance of
such effect. For example, given the sample size and
effect size we had in the current study, the power for
the immunoreactivity (reflected as the optical densities,
[OD]) of eNOS comparison between HBOT and NBA
group for spiral ganglion was 0.47. Future studies will
need to include larger numbers of animals in order to
confirm or refute these marginal findings.
To our knowledge, this is the first report of the upre-
gulation of constitutive NOS in some substructures of
the cochlea after HBOT treatment. Constitutive NOS
may act as a protective enzyme. In cerebrovascular
Figure 6 TUNEL assay of cochlea after HBOT. TUNEL assay of cochleae after HBOT. Significant DNA fragmentation was shown in the brain
tissue with penetrating injury (A-C); however, no evidence of DNA damage was identified in the cochlear tissue after HBOT (D-F).
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Page 6 of 10tissue, hyperbaric oxygen can elicit a vasorelaxing effect
from constitutively active NO by eNOS and nNOS [29],
although eNOS-derived NO may have some vasocon-
strictive effect during the early exposure to HBO [30].
NOS produces NO, which induces relaxation of the
smooth musculature and regulation of the vasotonia as
a microbiotic messenger [29]. Thus, the important role
of NO in cardioprotection [32] and cerebroprotection
[33] against ischemic damage is established. NO released
from constitutive NOS such as eNOS also protects
cochlear venules from excessive venular leakage [34]. In
contrast, iNOS usually has a devastating role in biologi-
cal processes. Induction of iNOS has also been demon-
strated in some cochlear pathologies like ischemia [13]
o rn o i s et r a u m a[ 1 7 ] .W h e nt h ec o c h l e ai se x p o s e dt o
h y p o x i co ri s c h e m i cc o n d i t i o n s ,t h ee x p r e s s e di N O S
may lead to an overexpression of peroxides [30], which
subsequently induce a direct toxic effect on neurons and
may affect the endocochlear potential. The synaptic
complex between the hair cells and the nerve fibers is
another region that the NO may exert its role [35]. NO
could inhibit the glutamate receptors by positive feed-
back under normoxic conditions. Conditions causing
cochlear hypoxia such as acoustic overstimulation may
induce glutamate release and calcium influx at the
synaptic complex between the hair cells and the nerve
fibers [35] and increase iNOS expression with excessive
formation of NO [17]. Upon glutamate release, overpro-
duction of iNOS-derived NO can further increase the
cochlear oxidative stress and cochlear dysfunction. In
this study, only constitutive NOS, especially eNOS, was
upregulated after HBOT, whereas iNOS was not immu-
noreactive. Thus, customary HBOT may play a thera-
peutic role rather than an adverse affect on cochlear
pathology.
Conclusion
This study showed a differential effect of HBOT on the
expression of NOS isoforms. Upregulation of constitu-
tive NOS was shown in the substructure of the cochlea
after HBOT, but iNOS was not expressed. Such observa-
tions should be extrapolated to the humans with cau-
tion, but support a therapeutic role for HBOT. There
were no significant changes in the eardrums or ABR
threshold shifts, and there was no obvious DNA frag-
mentation after HBOT in the guinea pig model.
Methods
Animals
Adult male albino guinea pigs (400-600 g, 10-14 weeks
of age) with intact Preyer reflexes and normal eardrums
were used in this study. Animals were housed in groups
under diurnal lighting conditions, and regular guinea pig
diet and water were provided ad libitum.A n i m a lu s e
protocols were approved by the China Medical Univer-
sity Committee on Use and Care of Animals (permission
number: 96-75-N). The experimental HBOT group
included five animals that received regular repetitive
HBOT (see below). The control, normobaric air (NBA)
group included five animals that did not receive HBOT
and were maintained in normobaric room air.
HBOT Model
Hyperbaric oxygen experiments were conducted in a
balloon-bag acrylic chamber inside a large pressure
chamber (Hyperbaric Oxygen Center in the China Med-
ical University Hospital). The HBOT protocol used in
the study was similar to the HBOT protocol used in
clinical practice for acute cerebral ischemia [18].
The temperature inside was maintained between 22 and
26°C with relative humidity at ~60%. The chamber pres-
sure was steadily increased to a pressure of 2.5 atmo-
sphere absolute (atm abs. or ATA). Compression and
decompression were carried out at a rate of 0.2 ATA/
min. Each treatment consisted of 17 min of compression
time, 60 min of stable compression time at 2.5 ATA and
13 min of decompression time. The animals were con-
tinuously observed during the course of HBOT to
manually adjust the oxygen ventilation rate and observe
the behavior of the animals, particularly for signs of
irritability or discomfort. A balloon that indicates the
pressure balance between the inside and outside of
the small chamber was mounted on the side wall of the
small acrylic chamber. The animals in the experimental
group received 20 HBOT treatments over a 4-week per-
iod (once per weekday, five times per week).
Otoscopic Evaluation
To minimize the frequency of anesthesia, visual assess-
ment of the tympanic membrane was performed asso-
ciated with the procedure for auditory brainstem
response (ABR) measurements (described below). After
guinea pigs were anesthetized with intramuscular injec-
tion of zoletil (30 mg/kg) and xylazine (10 mg/kg),
photographs of the tympanic membrane were obtained
using a Storz tele-otoscope. The severity of barotrauma
on the tympanic membrane was graded using a modi-
fied Teed classification scheme [36]: 0, normal; 1, slight
vascular injection or retraction of the eardrum; 2, mild
hemorrhage in the eardrum; 3, gross hemorrhage in the
eardrum; 4, hemotympanum; 5, tympanic membrane
perforation.
Auditory Test
Hearing tests were performed by tone burst ABR in a
sound-attenuated room, before and after completion of
the 20 HBOTs. The pure tone bursts were generated with
the amplitude specified by a real-time programmable
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http://www.biomedcentral.com/1471-2202/12/21
Page 7 of 10attenuator (Intelligent Hearing Systems, IHC Smart EP
version 3.97, Miami, FL, USA) with ER2 insert earphone,
with stimulus frequencies of 1, 2, 4 and 8 kHz (0.2-ms
rise/fall time and 1-ms flat segment) with maximal output
levels of 125, 123, 111 and 117 dB sound pressure level
(SPL). The tone bursts were produced by an IHS transdu-
cer (IHS Inc., Miami, FL, USA) in a closed acoustic system
through the sound delivery system. Responses for 1024
sweeps were averaged at each intensity level around the
threshold in 5-dB SPL steps. Threshold was defined as the
lowest intensity level at which a clear waveform was visible
in the evoked trace and was determined by visual inspec-
tion of the responses. At least two sequences of recordings
were made at the threshold intensity to verify the reprodu-
cibility of the ABR responses. ABR threshold at each time
and at each frequency was compared with the pre-surgical
threshold as a baseline. Threshold shift values were
estimated.
Immunohistochemistry
Animals were sacrificed after the 20 HBOT treatments.
They were first anesthetized by intramuscular injection
of zoletil (30 mg/kg) and xylazine (10 mg/kg) and then
perfused intracardially with 4% paraformaldehyde in
0.1 M phosphate-buffered solution (PBS) at pH 7.4. The
temporal bones and spleen tissues of the animals were
removed. The cochleae were opened at the apex and
round window and oval window membranes for better
penetration of the paraformaldehyde. The temporal
b o n e sw e r ei m m e r s e di nt h es a m ef i x a t i v eo v e r n i g h ta t
4°C. Decalcification was performed with 0.1 M EDTA
solution, buffered with PBS to pH 7.4, for 4 weeks at
4°C. Serial sections (7 μm thick) were cut using a micro-
tome in a plane parallel to the long axis of the cochlea
and mounted on silane-coated slides for further immu-
nohistochemical analysis. At least six sections obtained
from the modiolus in each animal were immunostained.
Serial sections (7 μm thick) of spleen tissue were also
cut using a microtome and mounted on silane-coated
slides for further immunohistochemical analysis to act
as positive control for the expression of iNOS.
A standard avidin-biotin-peroxidase (ABC) method
was used to locate NOS immunoreactive regions [37].
In brief, the sections were rinsed with 0.05 M Tris-buf-
fered solution (TBS) at pH 7.4 and then incubated in
3% H2O2 for 1 h, followed by 0.1% Triton X-100 in 10%
serum (normal goat serum [NGS] for eNOS/iNOS and
normal horse serum [NHS] for nNOS) for 1 h. Subse-
quently, samples were incubated overnight at 4°C with
the primary antibodies to nNOS (mouse monoclonal,
1:100, Santa Cruz Biotechnology, Santa Cruz, CA, USA),
eNOS (rabbit polyclonal, 1:1000, Santa Cruz Biotechnol-
ogy) or iNOS (rabbit polyclonal, 1:2000, Santa Cruz Bio-
technology). The sections were then incubated with the
secondary antibodies, either biotin-conjugated goat anti-
rabbit IgG for eNOS and iNOS or anti-mouse IgG for
nNOS (Sigma, St. Louis, MO, USA), diluted 1:200 in 2%
serum (NGS for eNOS and iNOS and NHS for nNOS).
The reaction was developed with a horseradish peroxi-
dase-streptavidin complex (Dako A/S, Denmark) at a
1:300 dilution for 1 h, followed by 0.06% 3,3’-diamino-
benzidine (DAB, Sigma) with 0.066% H2O2 substrate
medium in 0.05 M TBS. All specimens were then dehy-
drated in a graded series of ethanol and embedded in a
Clearmount mounting solution (Zymed, USA). Sections
from each of the experimental animals were immunos-
tained during the same run to allow comparisons across
the groups. The spleen from each animal was subjected
to the same fixation process, sectioned and immunos-
tained to serve as the iNOS-positive control. Sections
were photographed and analyzed using a Zeiss Axios-
kopz light microscope (Axioskop 2, Zeiss, Germany).
Semi-quantitative morphometric analysis
The intensities of nNOS and eNOS immunoreactivity
were measured in the cochlea by comparing the optical
densities (ODs) of the immunoreactivity in the control
(normal room air, NBA) and experimental (hyperbaric
oxygen treatment, HBOT) groups using the image analy-
zer (Image Pro Plus III, Media Cybernetics, USA) [38].
Two comparative paramodiolar sections were sampled
and analyzed from the apical to the basal turn of the
cochleae from both ears of each animal. Twenty different
cochlear sections were analyzed in each group, including
80 different regions of each Corti’s organ. The total areas
of the selected immunoreactive regions were calculated
and compared between the control and experimental
groups. The packing ODs of the target regions in each
cochlea were calculated and compared based on the sum-
mation of ODs relative to the selected areas in each
cochlear turn, from the apical to basal region.
Immunofluorescence labeling and confocal microscopy
To study the co-expression of nNOS and eNOS in the
cochlear sections, immunofluorescence labeling of eNOS
and nNOS was performed. The sections were rinsed
with 0.05 M TBS at pH 7.4 and then incubated in 3%
H2O2 for 1 h, followed by 0.1% Triton X-100/10% NGS
in PBS for 1 h. Subsequently, they were incubated over-
night at 4°C with the primary antibodies to nNOS
(1:100 dilution, Santa Cruz Biotechnology) and eNOS
(1:1000 dilution, Santa Cruz Biotechnology). The sec-
tions were then incubated with the secondary antibo-
dies, FITC-conjugated goat anti-mouse IgG for nNOS
and rhodamine-conjugated goat anti-rabbit IgG for
eNOS (Sigma), diluted 1:200 by 2% NGS in PBS. Finally,
the section slides were examined in a confocal laser
scanning microscope (LSM510, Zeiss).
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Page 8 of 10In situ detection of nuclear DNA fragmentation
We used the terminal deoxynucleotidyl transferase
(TdT)-mediated deoxyuridine triphosphate (dUTP)-bio-
tin nick end labeling (TUNEL) method to detect DNA
fragmentation. The TUNEL assay was performed using
an in situ cell death detection kit with a fluorescein
label (Roche Diagnostics GmbH, USA). The kit contains
TdT, which catalyzes the polymerization of fluorescein
dUTP to free 3’-OH DNA ends in a template-indepen-
dent manner. TUNEL-positive cells were identified by
incorporation of fluorescein-conjugated dUTP. Accord-
ing to the manufacturer’s instructions, the sections were
pre-treated with permeabilization solution (0.1% Triton
X-100 in 0.1% sodium citrate) for 2 min on ice (4°C)
and then incubated for 60 min at 37°C with the TUNEL
reaction mixture. After washing in PBS, sections were
photographed in a laser scanning confocal microscope
(Zeiss). Brain tissue from guinea pigs that suffered pene-
trating trauma (under anesthesia) 3 days prior to sacri-
fice was used as a positive control [39].
Statistical analysis
All values from groups of animals were presented in box
plots, which included medians, 25
th percentile, 75
th per-
centile, minimum and maximum. For the comparison
between groups, the nonparametric Mann-Whitney U
test contained in the SPSS program (version 12.0 for
Windows, SPSS Inc., Chicago, Illinois, USA) was
applied. The differences were considered to be statisti-
cally significant when p < 0.05.
Abbreviations used
ABR: auditory brainstem response; HBOT: hyperbaric oxygen therapy; NBA:
normobaric air; NO: nitric oxide; NOS: nitric oxide synthase; TUNEL: terminal
deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate
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